Epilepsy Is Heterogeneous in Early-Life Tuberous Sclerosis Complex

S Katie Z Ihnen1, Jamie K Capal2, Paul S Horn1

  • 1Division of Neurology, Cincinnati Children's Hospital Medical Center, Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio.

Pediatric Neurology
|August 3, 2021
PubMed

Insights

Epilepsy in tuberous sclerosis complex (TSC) presents variably in young children. Two distinct epilepsy profiles, favorable and unfavorable, were identified based on seizure burden, impacting developmental outcomes.

Area of Science:

  • Neurology
  • Pediatrics
  • Genetics

Background:

  • Epilepsy is common in tuberous sclerosis complex (TSC), often starting early and proving difficult to treat.
  • Significant individual variability exists in epilepsy presentation and severity within the TSC population.

Purpose of the Study:

  • To define distinct epilepsy profiles in young children with TSC using prospective seizure data.
  • To investigate the relationship between epilepsy profiles and developmental outcomes at 36 months.

Main Methods:

  • Longitudinal follow-up of children aged 0-36 months with TSC.
  • Daily seizure diaries maintained by caregivers for seizure type, onset, and count.
  • Hierarchical clustering analysis of six seizure burden metrics to identify epilepsy profiles.

Main Results:

  • Epilepsy affected 79% of participants, with 93% experiencing onset before 12 months.
  • Two distinct epilepsy profiles (favorable and unfavorable) were identified based on seizure burden.
  • Higher seizure burden was associated with poorer developmental outcomes at 36 months.

Conclusions:

  • Epilepsy in TSC is phenotypically diverse, with at least two discernible subpopulations based on seizure burden.
  • Early, targeted treatment strategies for TSC-related epilepsy should consider these distinct phenotypic profiles.
Abstract

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
475
Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
795
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
826
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
607
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
545